RIGL - Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
2025-05-07 18:16:40 ET
Summary
- Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock.
- Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments.
- R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets.
- Current share price below Buy Threshold offers a buying opportunity; plan to add positions if RIGL holds above $17.30 resistance and 200-Day EMA at $17.75.
As an analyst tracking small-cap biotech names, Rigel Pharmaceuticals, Inc. ( RIGL ) has always been one of my favorites, thanks to the company’s evolution from a TAVALISSE-centric company to a hematologic biotech that has multiple commercial products. It has been roughly seven months since my last Rigel article , where I reviewed the company’s Q2 2024 earnings and discussed the company’s growth opportunities and how that could have impacted the ticker’s valuation. Since then, the ticker is up over 20% and the company is showing absurd momentum on all fronts, which was showcased in their Q1 earnings , with a strong beat on EPS and revenue....
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum